Quest Diagnostics
- Market cap
- 25.06B
- P/E (TTM)i
- 24.10
- P/Bi
- 3.33
- EPSi
- 8.75
- Div yieldi
- 1.08%
- 52W posi
- 74%
Anonymous reader poll. Unscientific, not investment advice.
Quest Diagnostics last traded at 227.06, down 0.58% on the session. The company carries a market value of roughly 25.06B, the #767 most valuable US-listed company we track. Valuation-wise, the P/E sits at 24.74, 38% above the five-year average of 17.95. It pays a dividend yielding 1.08% on a trailing basis. Across 11 analysts the consensus rating is Buy, with an average price target of 255.00 (+12%). Over the past year the stock has ranged from 168.34 to 247.92; it now sits 74% up that band.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 30% of the universe, above its 200-day average.
- Signal has read BUY for 2 days.
- Its last 4 Buy calls have actually lost 3% on average three months out - the strategy's edge here has come from the basket, not from this ticker.
- Recent price momentum is +16.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 3.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 24.7x | Better than 37% |
| Forward P/E | 22.2x | Better than 36% |
| Price / Sales | 2.2x | Better than 60% |
| P/E vs own 5-yr range | 97th pctl | Better than 4% |
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 3.7% | Better than 37% |
| Net income CAGR (3Y) | 1.6% | Better than 41% |
| Free cash flow CAGR (3Y) | 1.1% | Better than 35% |
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 33.2% | Better than 33% |
| Operating margin | 14.1% | Better than 48% |
| Net margin | 9.0% | Better than 42% |
| Return on equity | 14.2% | Better than 52% |
| Return on invested capital | 8.6% | Better than 49% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 9.8% | Better than 75% |
| 6-month return | 18.5% | Better than 69% |
| 12-month return (ex latest month) | 34.6% | Better than 69% |
| Distance below 52-week high | 6.7% | Better than 86% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.0x | Better than 27% |
| Debt to assets | 40.6% | Better than 37% |
| Interest coverage | 5.8x | Better than 47% |
| Free cash flow / net income | 137.0% | Better than 67% |
Analyst View C-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 63.6% | Better than 38% |
| Upside to average target | 9.8% | Better than 17% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 228.39
- Open
- 228.51
- Day range
- 226.81 - 229.80
- Avg price
- 227.64
- Volume
- 927.43K
- Turnover
- 211.12M
- Turnover ratei
- 0.85%
- Volume ratioi
- 0.77
- Amplitudei
- 1.31%
- 52-week rangei
- 168.34 - 247.92
Valuation
- P/Ei
- 25.95
- P/E (TTM)i
- 24.10
- P/Bi
- 3.33
- EPSi
- 8.75
- Book value / shi
- 68.10
- Net profit
- 965.77M
- Net assets
- 7.52B
Share structure
- Market cap
- 25.06B
- Float capi
- 24.93B
- Shares out
- 110.37M
- Float sharesi
- 109.81M
Dividend & listing
- Div yield (TTM)i
- 1.08%
- Dividend (TTM)
- 2.46
- Listing date
- 1996-12-17
8.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+6.16M net over the window
Short interest
- Shares short
- 3.60M
- % of floati
- 3.26%
- Days to coveri
- 3.69
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Quest Diagnostics (DGX)?
Quest Diagnostics last traded at 227.06. The quote on this page refreshes every few seconds while US markets are open.
What is Quest Diagnostics's market cap?
About 25.06B.
What is the P/E ratio of Quest Diagnostics?
The trailing twelve-month P/E is 24.10, above its own 5-year average of 17.95 — toward the top of its historical range (96.81% percentile). See the Valuation tab for the full history.
Does Quest Diagnostics pay a dividend?
Yes. The trailing dividend yield is 1.08%. The 2025 payout was up 6.4% from 2024. See the Dividends tab for the full payment history.
Is Quest Diagnostics a buy according to analysts?
The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 255.00, which implies 12.3% upside from the current price. This is not investment advice.
What is Quest Diagnostics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Quest Diagnostics a B (Buy). Twelve-month momentum in the top 30% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 08:05:18 · For reference only, not investment advice and not tailored to your situation.